References
1. COVID-19 Map - Johns Hopkins Coronavirus Resource Center
2. MoHFW. MoHFW Home. Minist. Heal. Fam. Welfare, Gov. India2020;
3. Huang C et al. Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. www.thelancet.com 2020;395:497.
4. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus
Disease 2019 (COVID-19): A Review. JAMA - J. Am. Med. Assoc.2020;324(8):782–793.
5. WHO. Clinical management Clinical management : Living guidance
COVID-19. World Heal. Organ. 2021;(January).
6. Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. N.
Engl. J. Med. 2020;383(18). doi:10.1056/nejmcp2009249
7. Ministry of Health and Family Welfare. Clinical management
protocol : COVID-19. Version 32020;13.
8. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019
(COVID-19): Systematic review and meta-analysis. J. Intensive
Care 2020;8(1):36.
9. Arunachalam PS et al. Systems biological assessment of immunity to
mild versus severe COVID-19 infection in humans.. Science2020;6261(August):1–18.
10. Mathew D et al. Deep immune profiling of COVID-19 patients reveals
distinct immunotypes with therapeutic implications. Science (80-.
). 2020;369(6508). doi:10.1126/SCIENCE.ABC8511
11. Singh AK et al. Delineation of Homeostatic Immune Signatures
Defining Viremic Non-progression in HIV-1 Infection. Front.
Immunol. 2020;11(March):1–15.
12. Jagtap D et al. sMAdCAM:IL-6 ratio influences disease progression
and anti-viral responses in SARS-CoV-2 infection Dhanashree.